Product Description
| Brand |
Snibe |
| Sample Type |
Serum |
| Cancer Marker |
100T |
| CAT No. |
130201018M |
| Application |
Cancer Marker |
The kit has been designed for the quantitative determination of
Squamous Cell Carcinoma Antigen (SCCA) in human serum.
The method can be used for samples over the range of
0.13-100.0ng/ml. The test has to be performed on the Fully-auto
chemiluminescence immunoassay (CLIA) analyzer MAGLUMI
(Including Maglumi 600,Maglumi 1000,Maglumi 1000 Plus,
Maglumi 2000,Maglumi 2000 Plus,Maglumi 3000 and Maglumi
4000).
Advanced Oncology Biomarker DetectionThe Snibe MAGLUMI SCCA (CLIA) kit offers high sensitivity and specificity for squamous cell carcinoma antigen detection in serum or plasma. Its advanced chemiluminescence technology ensures precise quantification, supporting clinicians in both initial diagnosis and ongoing patient monitoring. The automated process integrated into MAGLUMI analyzers enhances workflow efficiency in clinical laboratories.
Seamless Integration with MAGLUMI AnalyzersSpecially designed for use with MAGLUMI Series Immunoassay Analyzers, this reagent kit enables streamlined, automated operation. Laboratories benefit from reduced manual intervention, real-time result delivery, and a user-friendly interface, ensuring consistent and accurate oncology testing outcomes.
Reliable Performance and Convenient StorageWith a 12-month shelf life and easy storage conditions (2-8C, protected from light), the Snibe SCCA assay maintains high stability. Laboratories can confidently manage inventory and planning, knowing the reagents are ready-to-use and deliver reliable data throughout their offering period.
FAQ's of Snibe MAGLUMI SCCA (CLIA):
Q: How does the Snibe MAGLUMI SCCA (CLIA) kit detect squamous cell carcinoma antigen?
A: The kit employs a two-step chemiluminescent immunoassay (CLIA) principle, enabling highly sensitive and specific detection of SCCA in human serum or plasma using automated MAGLUMI analyzers.
Q: What types of samples are compatible with this assay?
A: This assay is validated for use with human serum or plasma specimens, supporting versatile application in clinical settings for oncology diagnostics.
Q: When should the SCCA test be performed using this kit?
A: The test is suitable for both the initial detection and ongoing monitoring of squamous cell carcinoma in patients, as recommended by a healthcare professional.
Q: Where can the Snibe MAGLUMI SCCA kit be used?
A: It is intended for clinical laboratories equipped with the MAGLUMI Series Immunoassay Analyzers, making it ideal for hospital and reference lab oncology departments.
Q: What is the testing process for SCCA with this reagent kit?
A: Simply load the liquid reagents and calibrators into the compatible MAGLUMI analyzer, add patient samples, and initiate the fully automated analysis; results are typically available in about 30 minutes.
Q: What are the primary benefits of using the Snibe SCCA assay?
A: The assay provides high accuracy, sensitivity, and specificity in the quantification of SCCA, supporting clinicians with reliable data for diagnosis and patient management. Automation minimizes error and streamlines testing.
Q: What are the recommended storage conditions for this product?
A: Store the kit at 2-8C and protect it from light to maintain reagent integrity throughout its 12-month shelf life.